Details for Patent: 10,842,780
✉ Email this page to a colleague
Which drugs does patent 10,842,780 protect, and when does it expire?
Patent 10,842,780 protects MYRBETRIQ and is included in one NDA.
Protection for MYRBETRIQ has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has thirty-three patent family members in twenty-four countries.
Summary for Patent: 10,842,780
| Title: | Pharmaceutical composition for modified release |
| Abstract: | A pharmaceutical composition for modified release, comprising (1) (R)-2-(2-aminothiazol-4-yl)-4′-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide, or a pharmaceutically acceptable salt thereof, (2) at least one additive which ensures penetration of water into the pharmaceutical composition and which has a solubility such that the volume of water required for dissolving 1 g of the additive is 10 mL or less, and (3) a hydrogel-forming polymer having an average molecular weight of approximately 100,000 or more, or a viscosity of 12 mPa·s or more at a 5% aqueous solution at 25° C. is disclosed. |
| Inventor(s): | Yuuki Takaishi, Yutaka Takahashi, Takashi Nishizato, Daisuke Murayama, Emiko Murayama, Soichiro Nakamura, Kazuhiro Sako |
| Assignee: | Astellas Pharma Inc |
| Application Number: | US15/432,854 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 10,842,780 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Dosage form; |
Drugs Protected by US Patent 10,842,780
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apgdi | MYRBETRIQ | mirabegron | TABLET, EXTENDED RELEASE;ORAL | 202611-001 | Jun 28, 2012 | AB | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Apgdi | MYRBETRIQ | mirabegron | TABLET, EXTENDED RELEASE;ORAL | 202611-002 | Jun 28, 2012 | AB | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,842,780
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2009300752 | ⤷ Start Trial | |||
| Brazil | PI0919466 | ⤷ Start Trial | |||
| Canada | 2740342 | ⤷ Start Trial | |||
| China | 102170878 | ⤷ Start Trial | |||
| China | 105232448 | ⤷ Start Trial | |||
| Cyprus | 1123724 | ⤷ Start Trial | |||
| Denmark | 2345410 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
